[1]孔文强,文露,张春燕,等.卡格列净、恩格列净、达格列净治疗T2DM患者安全性的网状Meta分析[J].第三军医大学学报,2018,40(19):1792-1804.
 KONG Wenqiang,WEN Lu,ZHANG Chunyan,et al.Safety of canagliflozin, empagliflozin and dapagliflozin for T2DM patients: a network meta-analysis[J].J Third Mil Med Univ,2018,40(19):1792-1804.
点击复制

卡格列净、恩格列净、达格列净治疗T2DM患者安全性的网状Meta分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第19期
页码:
1792-1804
栏目:
临床医学
出版日期:
2018-10-15

文章信息/Info

Title:
Safety of canagliflozin, empagliflozin and dapagliflozin for T2DM patients: a network meta-analysis
作者:
孔文强文露张春燕杜彪
西南医科大学药学院;四川省人民医院药学部;川北医学院药学院;重庆三峡中心医院药学部
Author(s):
KONG Wenqiang WEN Lu ZHANG Chunyan DU Bia

School of Pharmacy, Southwest Medical University,  Luzhou, Sichuan Province, 646000; Department of Pharmacy, Sichuan Provincial People’s Hospital, Chengdu, Sichuan Province, 610072; School of Pharmacy, North Sichuan Medical Collage, Nanchong, Sichuan Province, 637000; Department of Pharmacy, Chongqing Three Gorges Central Hospital, Wanzhou, Chongqing, 404000, China
 

关键词:
SGLT22型糖尿病安全性网状Meta分析  
Keywords:
SGLIT2 type 2 diabetes mellitus safety network meta-analysis  
分类号:
R587.1; R589.1
文献标志码:
A
摘要:

目的     采用Meta分析研究评价卡格列净、恩格列净、达格列净治疗2型糖尿病患者的安全性。方法     检索PubMed、CENTRAL、Embase数据库,检索时限从建库到2018年1月,纳入有关RCT文献,传统Meta分析和网状Meta分析用STATA14完成。结果    共纳入34篇文献,含21 216名患者的35项RCT。Meta分析结果显示,卡格列净、恩格列净、达格列净与安慰剂和阳性药物相比:①均不会增加因不良反应退出人数,差异无统计学意义(P>0.05);②能够显著增加生殖器感染的人数,且女性感染人数要明显多于男性,差异均有统计学意义(P<0.05);③仅达格列净可轻微增加尿路感染人数[OR=1.26,95%CI(1.02~1.55),P=0.039]。④卡格列净与恩格列净[OR=1.53,95%CI(1.02~2.30)P<0.05]、安慰剂[OR=1.74,95%CI(1.32~2.30)P<0.05]相比,明显增加了低血糖发生人数。⑤恩格列净和达格列净与DPP4抑制剂、GLP1激动剂、二甲双胍、安慰剂相比,低血糖发生人数差异无统计学意义(P>0.05)。结论    卡格列净、恩格列净、达格列净治疗2型糖尿病,仅增加生殖器感染人数,有较好的耐受性和安全性;3种药物中恩格列净耐受性和安全性可能最好。

Abstract:

ObjectiveTo evaluate the safety of canagliflozin, empagliflozin and dapagliflozin in treatment of type 2 diabetes mellitus (T2DM) by network meta-analysis. MethodsThe databases including PubMed, Embase,and CENTRAL from inception to January 2018 were searched for eligible randomized controlled trials (RCTs) evaluating the SGLT2 inhibitors in T2DM patients. Conventional meta-analysis and network metaanalysis were performed by STATA14. ResultsA total of 34 studies, including 35 RCTs, involving 21 216 patients were collected. Meta-analysis showed that when compared with placebo and positive agents: ① the 3 drugs didn’t increase the number of patients who required discontinuation due to adverse events (P>0.05); ② they significantly increased the number of genital infections, especially in women, with significant differences (P<0.05). ③ Only dapagliflozin slightly raised the number of urinary tract infections (UTIs) (OR=1.26, 95%CI: 1.02~1.55, P=0.039); ④ Compared with empagliflozin (OR=1.53, 95%CI: 1.02~2.30, P<0.05) and placebo (OR=1.74, 95%CI: 1.32~2.30, P<0.05), canagliflozin slightly increased the incidence of hypoglycemia; ⑤ Empagliflozin and dapagliflozin didn’t increase the incidence of hypoglycemia,when compared with DPP-4 inhibitors, GLP-1 agonists, metformin and placebo (P>0.05). ConclusionCanagliflozin, empagliflozin and dapagliflozin show better tolerance and safety, though increasing the risk of genital infections in treatment of T2DM. Among them, empagliflozin may be the best in tolerance and durability.

参考文献/References:

[1]Executive summary: Standards of medical care in diabetes—2012[J]. Diabetes Care, 2012, 35(Suppl 1): S4-S10. DOI:10.2337/dc12s004.
[2]CHEN L, MAGLIANO D , ZIMMET P Z. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives[J]. Nat Rev Endocrinol, 2011, 8(4): 228-236. DOI:10.1038/nrendo.2011.183.
[3]JI L,HAN P,LIU Y,et al.Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea[J].Diabetes Obes Metab, 2015,17(1):23-31. DOI: 10.1111/dom.12385
[4]INZUCCHI S E,BERGENSTAL R M,BUSE J B,et al. Management of hyperglycaemia in type 2 diabetes: a patientcentered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetologia, 2012, 35(6): 1364-1379. DOI: 10.1007/s0012501225340
[5]BASILE J N. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reducecardiovascular risk in patients with type 2 diabetes (T2DM)[J]. J Diabetes Complicat, 2013,27(3):280-286. DOI: 10.1016/j.jdiacomp.2012.12.004
[6]SHYANGDAN D S,UTHMAN O A,WAUGH N,et al. SGLT2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network metaanalysis[J]. BMJ Open, 2016,6(2):e009417. DOI: 10.1136/bmjopen2015009417
[7]HIGGINS J P T,ALTMAN D G,STERNE A C. Chapter 8: Assessing risk of bias in included studies.[M]//Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011): The Cochrane Collaboration, 2011 Accessed August 15, 2016.
[8]HIGGINS J P,JACKSON D,BARRETT J K,et al. Consistency and inconsistency in network metaanalysis: concepts and models for multiarm studies[J]. Res Synth Methods, 2012,3(2): 98-110. DOI: 10.1002/jrsm.1044.
[9]VERONIKI A A, VASILIADIS H S, HIGGINS J P,et al. Evaluation of inconsistency in networks of interventions[J]. Int J Epidemiol,2013,42(1):332-345. DOI: 10.1093/ije/dys222.
[10]CHAIMANI A,SALANTI G. Using network metaanalysis to evaluate the existence of smallstudy effects in a network of interventions[J]. Res Synth Methods, 2012,3(2):161-176. DOI: 10.1002/jrsm.57.
[11]SALANTI G,ADES A E,IOANNIDIS J P. Graphical methods and numerical summaries for presenting results from multipletreatment metaanalysis: an overview and tutorial[J]. J Clin Epidemiol, 2011,64(2):163-171. DOI: 10.1016/j.jclinepi.2010.03.016.
[12]RODBARD H W,SEUFERT J,AGGARWAL N,et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin[J]. Diabetes Obes Metab,2016,18(8):812-819. DOI: 10.1111/dom.12684.
[13]NAUCK M A,DEL PRATO S, MEIER J J,et al. Dapagliflozin versus glipizide as addon therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin:a randomized, 52week, doubleblind, activecontrolled noninferiority trial[J]. Diabetes Care,2011,34(9):2015-2022. DOI: 10.2337/dc110606.
[14]HENRY R R,MURRAY A V,MARMOLEJO M H,et al. Dapagliflozin,metformin XR,or both:initial pharmacotherapy for type 2 diabetes,a randomised controlled trial[J]. Int J Clin Pract, 2012,66(5):446-456. DOI: 10.1111/j.17421241.2012.02911.x.
[15]LEITER L A,YOON K H,ARIAS P,et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin:a randomized, doubleblind,phase 3 study[J]. Diabetes Care,2015,38(3):355-364. DOI: 10.2337/dc132762.
[16]RIDDERSTRLE M,ANDERSEN K R,ZELLER C,et al. Comparison of empagliflozin and glimepiride as addon to metformin in patients with type 2 diabetes:a 104week randomised, activecontrolled, doubleblind, phase 3 trial[J].Lancet Diabetes Endocrinol, 2014,2(9):691-700. DOI: 10.1016/S22138587(14)701202.
[17]SCHERNTHANER G,GROSS J L,ROSENSTOCK J,et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52week randomized trial[J]. Diabetes Care, 2013,36(9):2508-2515. DOI: 10.2337/dc122491.
[18]STENLF K,CEFALU W T,KIM K A,et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise[J]. Diabetes Obes Metab, 2013,15(4):372-382. DOI: 10.1111/dom.12054.
[19]LAVALLEGONZáLEZ F J,JANUSZEWICZ A, DAVIDSON J,et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial[J]. Diabetologia, 2013,56(12):2582-2592. DOI: 10.1007/s0012501330391.
[20]WILDING J P,CHARPENTIER G,HOLLANDER P,et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial[J]. Int J Clin Pract, 2013,67(12):1267-1282. DOI: 10.1111/ijcp.12322.
[21]INAGAKI N, KONDO K, YOSHINARI T, et al. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24week, randomized, doubleblind, placebocontrolled,Phase III study[J]. Expert Opin Pharmacother, 2014,15(11):1501-1515. DOI: 10.1517/14656566.2014.935764
[22]FORST T,GUTHRIE R,GOLDENBERG R,et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone[J]. Diabetes Obes Metab, 2014,16(5):467-477. DOI: 10.1111/dom.12273.
[23]BODE B,STENLF K,HARRIS S,et al. Longterm efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes[J]. Diabetes Obes Metab, 2015,17(3):294-303. DOI: 10.1111/dom.12428.
[24]QIU R,CAPUANO G,MEININGER G. Efficacy and safety of twicedaily treatment with canagliflozin, a sodium glucose cotransporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus[J]. J Clin Transl Endocrinol, 2014,1(2):54-60. DOI: 10.1016/j.jcte.2014.04.001.
[25]ROSENSTOCK J,CHUCK L,GONZLEZORTIZ M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drugNave type 2 diabetes[J]. Diabetes Care, 2016, 39(3): 353-362. DOI: 10.2337/dc151736.
[26]RODEN M,MERKER L,CHRISTIANSEN AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drugnave patients with type 2 diabetes: a doubleblind extension of a Phase III randomized controlled trial[J].Cardiovasc Diabetol,2015,14:154. DOI: 10.1186/s1293301503140.
[27]SFTELAND E,MEIER J J,VANGEN B,et al. Empagliflozin as addon therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin:a 24week randomized,doubleblind,parallelgroup trial[J].Diabetes Care,2017,40(2):201-209. DOI: 10.2337/dc161347
[28]MERKER L,HRING H U,CHRISTIANSEN A V,et al. Empagliflozin as addon to metformin in people with Type 2 diabetes[J]. Diabet Med,2015,32(12):1555-1567. DOI: 10.1111/dme.12814.
[29]HRING H U,MERKER L,SEEWALDTBECKER E, et al. Empagliflozin as addon to metformin plus sulfonylurea in patients with type 2 diabetes: a 24week, randomized, doubleblind, placebocontrolled trial[J]. Diabetes Care, 2013,36(11):3396-3404. DOI: 10.2337/dc122673.
[30]KOVACS C S,SESHIAH V,MERKER L,et al. Empagliflozin as addon therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus[J]. Clin Ther, 2015,37(8):1773-1788. DOI: 10.1016/j.clinthera.2015.05.511.
[31]DEFRONZO R A,LEWIN A,PATEL S,et al. Combination of empagliflozin and linagliptin as secondline therapy in subjects with type 2 diabetes inadequately controlled on metformin[J]. Diabetes Care, 2015,38(3):384-393. DOI: 10.2337/dc142364
[32]LEWIN A,DEFRONZO R A,PATEL S,et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes[J]. Diabetes Care, 2015,38(3):394-402. DOI: 10.2337/dc142365.
[33]ROSENSTOCK J,JELASKA A,FRAPPIN G,et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes[J]. Diabetes Care,2014,37(7):1815-1823. DOI: 10.2337/dc133055.
[34]HADJADJ S,ROSENSTOCK J,MEINICKE T,et al. Initial combination of empagliflozin and metformin in patients with type 2 diabetes[J]. Diabetes Care, 2016,39(10):1718-1728. DOI: 10.2337/dc160522.
[35]JI L,LI H,MANSFIELD T A,et al. Dapagliflozin as monotherapy in drugnaive asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study[J]. Clin Ther, 2014,36(1):84-100. DOI: 10.1016/j.clinthera.2013.11.002
[36]FERRANNINI E, RAMOS S J, SALSALI A,et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, doubleblind, placebocontrolled, phase 3 trial[J]. Diabetes Care, 2010,33(10):2217-2224. DOI: 10.2337/dc100612.
[37]ROSENSTOCK J,HANSEN L,ZEE P, et al. Dual addon therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized doubleblind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin[J]. Diabetes Care, 2015,38(3):376-383. DOI: 10.2337/dc141142.
[38]BAILEY C J,GROSS J L,HENNICKEN D, et al. Dapagliflozin addon to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, doubleblind, placebocontrolled 102week trial[J]. BMC Med, 2013,11:43. DOI: 10.1186/174170151143.
[39]FRAS J P,GUJA C,HARDY E,et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION8):a 28 week, multicentre,doubleblind,phase 3,randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2016,4(12):1004-1016. DOI: 10.1016/S22138587(16)302674.
[40]STROJEK K,YOON K H,HRUBA V,et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, doubleblind, parallelgroup, placebocontrolled trial[J]. Diabetes Ther,2014,5(1):267-283. DOI: 10.1007/s1330001400720.
[41]JABBOUR S A,HARDY E,SUGG J,et al. Dapagliflozin is effective as addon therapy to sitagliptin with or without metformin:a 24week,multicenter,randomized,doubleblind,placebocontrolled study[J]. Diabetes Care,2014,37(3):740-750. DOI: 10.2337/dc130467.
[42]BAILEY C J,IQBAL N,T’JOEN C,et al. Dapagliflozin monotherapy in drugnave patients with diabetes:a randomizedcontrolled trial of lowdose range[J]. Diabetes Obes Metab,2012,14(10):951-959. DOI: 10.1111/j.14631326.2012.01659.x.
[43]BOLINDER J, LJUNGGREN , KULLBERG J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin[J]. J Clin Endocrinol Metab,2012,97(3):1020-1031. DOI: 10.1210/jc.20112260.
[44]WILDING J P,WOO V,SOLER NG,et al. Longterm efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial[J]. Ann Intern Med, 2012,156(6):405-415. DOI: 10.7326/00034819156620120320000003.
[45]孙静媛,马丽娜,高凌. 钠葡萄糖共转运蛋白1和2的研究新进展[J]. 世界华人消化杂志, 2016,24(25):3673-3682. DOI: 10.11569/wcjd.v24.i25.3673.
SUN J Y,MA L N,GAO L. New perspectives on research of sodiumglucose cotransporters1 and 2[J]. World Chin J Diges,2016,24(25):3673-3682. DOI: 10.11569/wcjd.v24.i25.3673.
[46]HALIMI S,VERGS B. Adverse effects and safety of SGLT2 inhibitors[J]. Diabetes Metab,2014,40(6 Suppl 1):S28-34. DOI: 10.1016/S12623636(14)72693X.
[47]LI D, WANG T, SHEN S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodiumglucose cotransporter 2 inhibitors: A metaanalysis of randomized controlled trials[J]. Diabetes Obes Metab, 2017,19(3):348-355. DOI: 10.1111/dom.12825.

相似文献/References:

[1]李亚,李伟,王晶,等.抑郁状态与2型糖尿病形成各阶段代谢指标的相关性分析[J].第三军医大学学报,2012,34(16):1697.
[2]陈志雄,张军,张刘平,等.胃转流术降低2型糖尿病大鼠肝脏FoxO1因子的表达[J].第三军医大学学报,2012,34(17):1766.
 Chen Zhixiong,Zhang Jun,Zhang Liuping,et al.Effect of gastric bypass on FoxO1 expression in liver of rats with type 2 diabetes[J].J Third Mil Med Univ,2012,34(19):1766.
[3]杨静,张朝军,郑宏庭,等.胃转流手术治疗肥胖2型糖尿病短期疗效观察[J].第三军医大学学报,2012,34(21):2222.
[4]金晖,鲍洁,赵镇,等.米格列奈与瑞格列奈对新诊断2型糖尿病的临床疗效研究[J].第三军医大学学报,2013,35(03):260.
 Jin Hui,Bao Jie,Zhao Zhen,et al.Clinical efficacy of mitiglinide and repaglinide in treatment of patients with newly diagnosed type 2 diabetes mellitus[J].J Third Mil Med Univ,2013,35(19):260.
[5]廖涌,章婧,李阳,等.甘精胰岛素联合门冬胰岛素在2型糖尿病围手术期的临床应用[J].第三军医大学学报,2008,30(18):1766.
 LIAO Yong,ZHANG Jing,LI Yang,et al.Insulin glargine plus insulin aspart for perioperative patients with type 2 diabetes[J].J Third Mil Med Univ,2008,30(19):1766.
[6]卢薇,欧亚萍,梁英梅.二甲双胍对2型糖尿病患者血HS-CRP、TNF-α、ICAM-1水平的影响[J].第三军医大学学报,2008,30(18):1768.
[7]刘红,罗蕾,高原.2型糖尿病大鼠近球小管Na+,K+-ATPase活性变化[J].第三军医大学学报,2006,28(20):2062.
[8]贾贺堂,张素华,纪立农,等.北京地区早发糖尿病家系MODY5基因突变的筛查[J].第三军医大学学报,2006,28(19):1952.
[9]杨孟雪,甘华,沈清,等.1, 25-(OH)2D3及LPS对2型糖尿病肾病尿毒症患者单核细胞维生素D受体表达的影响[J].第三军医大学学报,2011,33(16):1731.
 Yang Mengxue,Gang Hua,Sheng Qing,et al.Effect of 1,25-(OH)2D3 and LPS on expression of vitamin D receptor in human monocytes incubated with sera from type 2 diabetes patients and diabetic nephropathy patients with uremia[J].J Third Mil Med Univ,2011,33(19):1731.
[10]张学亮,冯晓丽,徐静,等.曲美他嗪对2型糖尿病患者血乳酸水平的影响[J].第三军医大学学报,2005,27(24):2478.

更新日期/Last Update: 2018-10-17